A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

This phase III trial tests penpulimab — an anti-PD-1 immunotherapy drug — in patients with classical Hodgkin's lymphoma that has relapsed (come back) or is refractory (not responding) after prior treatments, including stem cell transplant or multiple chemotherapy regimens. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of classical Hodgkin's lymphoma - Your lymphoma has relapsed or did not respond after autologous stem cell transplant, OR you have had at least 2 prior lines of chemotherapy without transplant - You have at least one measurable lesion on imaging - Your ECOG performance status is 0 or 1 (functional with minimal symptoms) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have active autoimmune disease - You have active or uncontrolled infections - You are pregnant or breastfeeding - You have had prior treatment with an anti-PD-1 or anti-PD-L1 immunotherapy Talk to your doctor to see if this trial is right for you.